OAM
IMVT icon

Oxford Asset Management’s Immunovant IMVT Stock Holding History

Oxford Asset Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,456
Closed -$309K – 495
2026
Q1 		$309K Buy
+12,456
New +$322K 0.12% 250
2025
Q3 		– Sell
-11,717
Closed -$187K – 591
2025
Q2 		$187K Buy
+11,717
New +$177K 0.06% 435

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Oxford Asset Management's IMVT Position: Q2 2026 in Review

Oxford Asset Management sold out of Immunovant (IMVT) in Q2 2026, closing a stake of 12,456 shares — an estimated $309K sold.

Oxford Asset Management first reported a position in IMVT in Q2 2025 and held it in 2 quarters. The position peaked at $309K in Q1 2026. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Oxford Asset Management reported no remaining Immunovant position as of Q2 2026 after selling out during the quarter.
  • Oxford Asset Management sold 12,456 Immunovant shares in Q2 2026, an estimated $309K.
  • Oxford Asset Management first reported a position in Immunovant in Q2 2025 and held it in 2 quarters.
  • Oxford Asset Management's Immunovant position peaked at $309K in Q1 2026.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Oxford Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.